Table 3 Objective response to talabostat.
From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Age/Sex (Patient No.) | M classification at enrollmenta | Metastatic sites at enrollment | Prior Tx for Stage IV diseaseb | Best response to prior Tx | Response to talabostat | Duration of Response (days) |
|---|---|---|---|---|---|---|
54/F (01-003) | M1b | Skin, lung | Tumor peptide heat shock (Vitespen) | PD | PR | 151 |
46/M (04-002) | M1b | Lung | Sargramostim | PD | PR | 62 |
63/M (04-003) | M1b | Lung | None | NA | PR | 287 |
61/F (06-001) | M1c | Subcutaneous tissue, stomach, lymph node(s), visceral | Temozolomide, thalidomide | SD | PR | Unknownc |
53/M (09-014) | M1c | Regional lymph node(s), liver | None | NA | PR | 176 |
58/F (12-003) | M1c | Lymph nodes beyond regional, lung, abdominal wall | None | NA | PR | 141 |